Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-31-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0044H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Cell culture lysate, Whole blood

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

6.25 – 0.195 amol/μl

Limit of Detection

0.065 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 3.8%

Inter-assay (Run-to-Run)

n = 5,
CV = 3.6%

Spiking Recovery

99.5%

Dilution Linearity

103.9%

Specificity

Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.

Note

Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.


Product Manual: miREIA - microRNA enzyme immunoassay

 

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-31-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in the pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miRNA-31, including its mature forms miR-NA-31-3p and miRNA-31-5p, has a dual role, both oncogenic and tumor-suppressing, being disrupted in many human cancers. Aberrant expression of miR-31-5p has been detected in various cancers and plays a significant role in tumorigenesis. Low miR-31-5p expression was present in nasopharyngeal carcinoma tissues and cell lines and acted as a tumor suppressive miRNA and low expression of miR-31-5p was highly correlated with tumor-node-metastasis stage. Serum miR-31-5p levels were significantly different between oral cancer patients and healthy controls and between pre- and postoperative patients. Furthermore, a miR-31-5p mimic enhanced the proliferation of normal epithelial cells, and antagomiR-31-5p inhibited the proliferation of oral cancer cells. miR-31-5p was proven to have oncogenic properties in both colorectal cancer (CRC) cell lines and primary colorectal tumors. In CRC, miR-31-3p and miR-31-5p dysregulation seems to have a particular role in response to treatment with anti-EGFR therapy. miR-31-5p was significantly down-regulated in renal cell carcinoma (RCC) tissues and cell lines compared with paired adjacent normal tissues and normal cell lines. miR-31-5p downregulation was associated with poor prognosis in RCC patients. Overexpression of miR-31-5p inhibited RCC cell proliferation, migration and invasion and cell cycle.

Besides cancer, it was found that miR-31-5p was up-regulated in sera from patients with preeclampsia and in human endothelial cells treated with TNFα. TNFα-mediated induction of miR-31-5p was blocked by an NF-κB inhibitor. It was suggest that NF-κB-responsive miR-31-5p elicits endothelial dysfunction, hypertension, and vascular remodeling via post-transcriptional down-regulation of eNOS and is a molecular risk factor in the pathogenesis and development of preeclampsia.

Summary References (5)

References to miR-31-5p

  • Kim S, Lee KS, Choi S, Kim J, Lee DK, Park M, Park W, Kim TH, Hwang JY, Won MH, Lee H, Ryoo S, Ha KS, Kwon YG, Kim YM. NF-κB-responsive miRNA-31-5p elicits endothelial dysfunction associated with preeclampsia via down-regulation of endothelial nitric-oxide synthase. J Biol Chem. 2018 Dec 7;293(49):18989-19000. doi: 10.1074/jbc.RA118.005197. Epub 2018 Oct 2. PMID: 30279269; PMCID: PMC6295733. See more on PubMed
  • Lei SL, Zhao H, Yao HL, Chen Y, Lei ZD, Liu KJ, Yang Q. Regulatory roles of microRNA-708 and microRNA-31 in proliferation, apoptosis and invasion of colorectal cancer cells. Oncol Lett. 2014 Oct;8(4):1768-1774. doi: 10.3892/ol.2014.2328. Epub 2014 Jul 9. PMID: 25202407; PMCID: PMC4156175. See more on PubMed
  • Li Y, Quan J, Chen F, Pan X, Zhuang C, Xiong T, Zhuang C, Li J, Huang X, Ye J, Zhang F, Zhang Z, Gui Y. MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1). Biomed Pharmacother. 2019 Mar;111:517-526. doi: 10.1016/j.biopha.2018.12.102. Epub 2018 Dec 28. PMID: 30597305. See more on PubMed
  • Lu Z, He Q, Liang J, Li W, Su Q, Chen Z, Wan Q, Zhou X, Cao L, Sun J, Wu Y, Liu L, Wu X, Hou J, Lian K, Wang A. miR-31-5p Is a Potential Circulating Biomarker and Therapeutic Target for Oral Cancer. Mol Ther Nucleic Acids. 2019 Jun 7;16:471-480. doi: 10.1016/j.omtn.2019.03.012. Epub 2019 Apr 11. PMID: 31051332; PMCID: PMC6495075. See more on PubMed
  • Yi SJ, Liu P, Chen BL, Ou-Yang L, Xiong WM, Su JP. Circulating miR-31-5p may be a potential diagnostic biomarker in nasopharyngeal carcinoma. Neoplasma. 2019 May 11;2019:181109N847. PMID: 31088103. See more on PubMed
Related Products Docs